BSE Live
Apr 10, 16:01Prev. Close
541.45
Open Price
552.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 10, 15:42Prev. Close
541.85
Open Price
538.00
Bid Price (Qty.)
558.70 (20)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Orchid Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 50.72 | 50.72 | 40.82 | 40.82 | 40.82 | |
| Total Share Capital | 50.72 | 50.72 | 40.82 | 40.82 | 40.82 | |
| Reserves and Surplus | 1,273.33 | 1,167.60 | 691.15 | 637.14 | 640.52 | |
| Total Reserves and Surplus | 1,273.33 | 1,167.60 | 691.15 | 637.14 | 640.52 | |
| Total Shareholders Funds | 1,324.05 | 1,218.32 | 731.96 | 677.95 | 681.34 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 131.64 | 120.21 | 148.84 | 208.17 | 427.50 | |
| Deferred Tax Liabilities [Net] | 0.00 | 0.00 | 3.23 | 3.23 | 3.23 | |
| Other Long Term Liabilities | 0.04 | 0.37 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 3.39 | 3.63 | 12.60 | 11.01 | 11.54 | |
| Total Non-Current Liabilities | 135.06 | 124.21 | 164.67 | 222.40 | 442.26 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 42.60 | 14.05 | 182.51 | 59.79 | 2.84 | |
| Trade Payables | 170.48 | 179.39 | 136.52 | 120.74 | 68.74 | |
| Other Current Liabilities | 22.03 | 14.15 | 4.11 | 10.30 | 25.76 | |
| Short Term Provisions | 2.37 | 2.08 | 3.49 | 3.01 | 3.52 | |
| Total Current Liabilities | 237.47 | 209.67 | 326.63 | 193.83 | 100.87 | |
| Total Capital And Liabilities | 1,696.58 | 1,552.20 | 1,223.26 | 1,094.19 | 1,224.47 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 612.46 | 615.79 | 572.67 | 583.32 | 670.02 | |
| Intangible Assets | 0.79 | 0.64 | 0.39 | 0.34 | 0.37 | |
| Capital Work-In-Progress | 27.69 | 10.18 | 46.09 | 9.78 | 7.43 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 657.16 | 640.89 | 619.15 | 593.44 | 677.82 | |
| Non-Current Investments | 69.35 | 69.40 | 50.12 | 49.01 | 0.40 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 108.24 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 75.44 | 59.62 | 60.20 | 16.43 | 4.00 | |
| Total Non-Current Assets | 910.19 | 769.91 | 729.46 | 658.88 | 682.22 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 15.02 | |
| Inventories | 326.37 | 264.23 | 228.74 | 172.66 | 150.57 | |
| Trade Receivables | 241.83 | 189.37 | 211.91 | 160.23 | 131.96 | |
| Cash And Cash Equivalents | 164.28 | 257.23 | 22.34 | 4.21 | 18.97 | |
| Short Term Loans And Advances | 0.00 | 7.89 | 4.70 | 0.00 | 0.00 | |
| OtherCurrentAssets | 53.90 | 63.58 | 26.11 | 98.22 | 225.73 | |
| Total Current Assets | 786.39 | 782.29 | 493.79 | 435.31 | 542.25 | |
| Total Assets | 1,696.58 | 1,552.20 | 1,223.26 | 1,094.19 | 1,224.47 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 543.77 | 59.23 | 44.91 | 24.87 | 45.31 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 281.01 | 0.00 | 248.98 | 195.07 | 166.98 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.23 | 0.00 | 7.71 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 21.28 | 0.00 | 14.76 | 9.83 | 5.22 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 715.03 | -- | 545.17 | 483.03 | 396.64 | |
| Other Earnings | -- | -- | -- | -- | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 17.38 | 17.38 | 17.38 | 17.38 | 17.38 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | 0.25 | 0.14 | 0.09 | 0.13 | |
| Non-Current Investments Unquoted Book Value | -- | 69.15 | 174.68 | 173.69 | 125.04 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
17.11.2025
Orchid Pharma Consolidated September 2025 Net Sales at Rs 193.52 crore, down 13.1% Y-o-Y
12.11.2025
Orchid Pharma Standalone September 2025 Net Sales at Rs 193.52 crore, down 13.1% Y-o-Y
09.09.2025
Orchid Pharma Standalone June 2025 Net Sales at Rs 172.93 crore, down 29.25% Y-o-Y
27.05.2025
Orchid Pharma Standalone March 2025 Net Sales at Rs 237.48 crore, up 9.39% Y-o-Y
17.11.2025
Orchid Pharma Consolidated September 2025 Net Sales at Rs 193.52 crore, down 13.1% Y-o-Y
12.11.2025
Orchid Pharma Standalone September 2025 Net Sales at Rs 193.52 crore, down 13.1% Y-o-Y
09.09.2025
Orchid Pharma Standalone June 2025 Net Sales at Rs 172.93 crore, down 29.25% Y-o-Y
27.05.2025
Orchid Pharma Standalone March 2025 Net Sales at Rs 237.48 crore, up 9.39% Y-o-Y
12.02.2014
10.04.2026
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth